

14TH DRESDEN SYMPOSIUM ON AUTOANTIBODIES

Dresden, September 10-13, 2019

5th International Consensus on ANA Pattern (ICAP) Workshop
4th International Autoantibody Standardization (IAS) Workshop

September 09, 2019

Messe Dresden (Dresden Fair),
Messering 6, Tor 1, 01067 Dresden



Final Programme

Congress venue of the 14th Dresden Symposium on Autoantibodies: the modern Dresden Fair and the historical Stock Market Dresden.



WELCOME

Dear Colleagues,

On behalf of the Organizing Committee it is a great pleasure to welcome you to our 14th Dresden Symposium on Autoantibodies. The symposium is organized by the Institute of Immunology of the Medical Faculty of the Technical University Dresden in cooperation with the Society for the Advancement of Immunodiagnosics (www.gfid-ev.de) and the Section Immunodiagnosics of the German Society for Clinical Chemistry and Laboratory Medicine (www.dgkl.de). The current symposium focuses on different aspects of the role of autoantibodies (AABs) in the prediction and care of autoimmune diseases. An attractive scientific program has been developed together with the Co-chairs and the International Advisory Board as well as the Advisory Board of the Society for the Advancement of Immunodiagnosics, which represents also the DGKL Section of Immunodiagnosics. We would like to express our thanks to the members of the International Advisory Board and to the active contributors who will present their latest achievements, as well as to the numerous sponsors who enabled this symposium.

Autoimmune diseases (AID) are complex immune-mediated conditions which comprise a large spectrum of clinical manifestations. Non-disease specific symptoms at early stages of disease, common clinical features between different diseases, the heterogeneity of molecular mechanisms within the same disease class and problems in differentiation from non-auto-immune causes may delay correct diagnosis and adequate treatment decisions. Besides improvement of diagnostics, finding new treatments or applying the existing ones in a more effective way are major challenges in the care of AID. Precision medicine has been regarded as an approach to find solutions for better treatment and even disease prevention based on people's individual differences in environment, genes and lifestyle. Novel AABs, AABs against modified autoantigens, the use of AAB profiles and the combination of AABs with other biomarkers may help to diagnose AID earlier as well as to reclassify AID, which might result in a more homogenous stratification in terms of disease course and manifestations and effective treatment requirements. Developments and challenges in this context have been shown especially for systemic AID (e.g., rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies) but also for autoimmune neurologic, heart and gastrointestinal diseases. A further improvement of diagnostic accuracy through standardization/harmonization of the detection methods, as well as optimization of established methods and introduction of novel assays and novel AABs in routine diagnostics are major prerequisites for using AABs in precision medicine. The current symposium also highlights important developments of the last years regarding methodological aspects and diagnostic strategies of AAB determinations.

As the 14th Dresden Symposium on Autoantibodies focuses again on methodical aspects of autoantibody testing, we are delighted to host the 5th International Consensus on ANA Pattern (ICAP) Workshop and the 4th International Autoantibody Standardization (IAS) Workshop. We expect that our 14th Dresden Symposium on Autoantibodies as well as the ICAP and IAS workshops will stimulate a broad debate on how the new achievements from the bench work could help to improve diagnostics and therapy of autoimmune diseases. We hope that you will enjoy the scientific programme and your stay in Dresden.

Karsten Conrad
On behalf of the Organizing Committee

07.30-08.30

**Early bird meeting with Diagnostic Companies:
Adopting reference materials?** *Johanna Sheldon (London, UK)*
Meeting room "Palaiszimmer"

5th International Consensus on ANA Pattern (ICAP) Workshop

(Sponsored by the German United Society for Clinical Chemistry and Laboratory Medicine)

Co-Chairs: Edward K.L. Chan, Luis E.C. Andrade

08.30-10.30

5th ICAP WORKSHOP PART I

Welcome and agenda. *Edward K.L. Chan (Gainesville, USA)*

International Consensus on ANA pattern (ICAP) in 2019:
Status und Future Directions. *Edward K.L. Chan (Gainesville, USA)*

Mixed and multiple ICAP patterns – Definition and clinical
relevance. *Luis E.C. Andrade (São Paulo, Brazil)*

"New" patterns:

- Pseudo-DFS pattern. *Luis E.C. Andrade (São Paulo, Brazil),
Carlos Casiano (Loma Linda, USA)*
- Dissecting pleomorphic patterns: PCNA, SG2NA (AC-30)
and Pseudo-PCNA patterns. *Manfred Herold, Werner Klotz
(Innsbruck, Austria)*
- SS-A/Ro60 pattern. *Luis E.C. Andrade (São Paulo, Brazil),
Karsten Conrad (Dresden, Germany)*

10.30-11.00

COFFEE BREAK

11.00-13.00

5th ICAP WORKSHOP PART II

ICAP consensus in reporting ANA.
Carlos von Muhlen (San Diego, USA)

ICAP questionnaire. *Lieve Van Hoovels (Leuven, Belgium)*

ICAP training module #1. *Wilson de Melo Cruvinel
(Goiania-Goiás, Brazil), Alessandra Dellavance (São Paulo,
Brazil), Luis E.C. Andrade (São Paulo, Brazil), Edward K.L. Chan
(Gainesville, USA)*

Collaborative project to define clinical relevance and antigenic
associations of certain AC patterns. *Luis E.C. Andrade (São Paulo,
Brazil), Trischna Martins (Wendelsheim, Germany)*

Report from AMLI Workshop. *Marvin J. Fritzler (Calgary, Canada)*

Discussion and conclusions

13.00-14.00

LUNCH BREAK

4th International Autoantibody Standardization (IAS) Workshop

(Sponsored by the German Society for Clinical Chemistry
and Laboratory Medicine)

Co-Chairs: Joanna Sheldon, Pier Luigi Meroni

4th IAS WORKSHOP PART I

14.00-16.00

Why we are still discussing standardization of autoantibody
measurements? *Joanna Sheldon (London, UK)*

Overview on the existing standardization initiatives on
autoantibody testing. *Pier Luigi Meroni (Milan, Italy)*

Initiatives of the IFCC Committee on Harmonization of
Autoantibody Testing (C-HAT)

- PR3- and MPO-ANCA. *Joanna Sheldon (London, UK)*
- Anti-beta2-GPI antibody. *Evanthia Monogioudi (Geel, Belgium)*
- Further and future plans

Activities of the National Institute for Biological Standards and
Control (NIBSC)

- RF/ACPA update. *Lucy Studholme, Bernhard Fox (Hertfordshire, UK)*
- dsDNA antibody update. *Johan Rönnelid (Uppsala, Sweden), Bernard Fox (Hertfordshire, UK)*
- Further and future plans

The Autoantibody Standardization Committee (ASC) of the
International Union of Immunological Societies (IUIS)

- Anti-DSF70 antibody. *Luis E.C. Andrade (São Paulo, Brazil)*
- Current and new reference materials. *Bing Zheng, Edward K.L. Chan (Shanghai, China / Gainesville, USA)*
- Further and future plans

COFFEE BREAK

16.00-16.30

4th IAS WORKSHOP PART II

16.30-18.30

The new EULAR initiative -The strategy of the Task Force.
Pier Luigi Meroni (Milan, Italy), Johan Rönnelid (Uppsala, Sweden)

Standardization through harmonization of test result interpretation.
Xavier Bossuyt (Leuven, Belgium)

General Discussion

TUESDAY
SEPTEMBER 10

08.00-22.00

Registration

10.00-10.30

Welcome and Introduction

Autoantibodies in personalized medicine –
current stage and challenges
Karsten Conrad (Dresden Germany)

10.30-12.15

**PRECISION MEDICINE IN THE CARE OF
AUTOIMMUNE DISEASES – GENERAL ASPECTS**

Co-Chairs: Karsten Conrad (Dresden, Germany)
Yehuda Shoenfeld (Tel Hashomer, Israel)

10.30-11.10

Autoimmune dysautonomia – An umbrella for many old entities
Yehuda Shoenfeld (Tel Hashomer, Israel)

11.10-11.50

Pragmatic aspects of precision health
Marvin J. Fritzler (Calgary, Canada)

11.50-12.15

AutoPredict of autoimmune rheumatic diseases: a novel approach
to predict response to treatment based on autoantibody, cytokine
and immunobiological markers
Dimitrios Bogdanos (Larissa, Greece)

12.15-13.30

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

**Posters A1 – A39 (AUTOANTIBODIES IN SYSTEMIC
AUTOIMMUNE DISEASES):** Guided poster presentation of
selected posters chaired by Thorsten Krieger

13.30-15.30

**PRECISION MEDICINE IN THE CARE OF AUTOIMMUNE
DISEASES – SPECIAL ASPECTS**

Co-Chairs: Marvin Fritzler (Calgary, Canada)
Elena Csernok (Kirchheim, Germany)

13.30-13.55

Autoantibodies in the management of individual patients with
connective tissue disease – A Rheumatologist's perspective
Martin Aringer (Dresden, Germany)

13.55-14.20

Precision medicine in the care of Rheumatoid Arthritis
Michael Mahler (San Diego, USA)

14.20-14.45

Risk stratification of patients with Antiphospholipid Syndrome
Savino Sciascia (Turin, Italy)

14.45-15.10

A new approach for classification of autoimmune myositis
Yves Allenbach (Paris, France)

15.10-15.30

Vasculitis biomarkers in the era of personalized medicine
Elena Csernok (Kirchheim, Germany)

COFFEE BREAK

15.30-16.00

AUTOIMMUNE DISEASES WITH RENAL INVOLVEMENT
(sponsored by EUROIMMUN Medizinische Labordiagnostika AG)

16.00-18.00

Co-Chairs: Stanley Naides (Mountain Lakes, USA)
Lorenz Risch (Liebefeld, Switzerland)

Diagnostic advances in membranous nephropathy
Oliver Sindscheid (Lübeck, Germany)

16.00-16.20

Uromodulin – An old acquaintance appearing in the spotlight
Lorenz Risch (Liebefeld, Switzerland)

16.20-16.40

Urinary soluble CD163 predicts disease activity in patients
with ANCA-associated crescentic glomerulonephritis
Joop Aendekerk (Maastricht, The Netherlands)

16.40-17.00

ANCA diagnostics – An update
Kai Fechner (Lübeck, Germany)

17.00-17.20

PR3 and PLA2R using the chemiluminescence technique
Panagiotis Grypiotis (Lübeck, Germany)

17.20-17.40

Autoimmune neurology: From antigen discovery to
product development
Ramona Miske (Lübeck, Germany)

17.40-18.00

**GET TOGETHER IN THE INDUSTRIAL EXHIBITION –
POSTER AND EXHIBITION VIEWING**

18.00-22.00

08.30-10.30

CLOSING THE GAP IN AUTOIMMUNITY: A MODERN APPROACH (sponsored by Inova Diagnostics, Inc.)

Co-Chairs: Michael Mahler (San Diego, USA)
Rene E.M. Toes (Leiden, The Netherlands)

08.30-08.55

Understanding and addressing gaps in autoantibody testing:
Requirements for precision health
Marvin J. Fritzler (Calgary, Canada)

08.55-09.15

Anti-PAD antibodies in the serology of rheumatoid arthritis
Laura Martinez Prat (San Diego, USA)

09.15-09.35

Autoantibodies in myositis measured using a novel particle based
multi-analyte technology
Michael Mahler (San Diego, USA)

09.35-09.55

Autoantibody profiling in Celiac disease: The value beyond tTG IgA
Xavier Bossuyt (Leuven, Belgium)

09.55-10.15

Performance evaluation of the Aptiva Antiphospholipid
Syndrome panel
Savino Sciascia (Turin, Italy)

10.15-10.30

Glycosylation of antibodies in autoimmune diseases –
Special focus on Fab glycans
Rene E.M. Toes (Leiden, The Netherlands)

10.30-11.00

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

11.00-12.30

AUTOANTIBODIES IN CARDIOVASCULAR DISEASES

Co-Chairs: Yehuda Shoenfeld (Tel Hashomer, Israel)
Gabriela Riemekasten (Lübeck, Germany)

11.00-11.25

Autoimmune cardiac channelopathies
Mohamed Boutjdir (New York, USA)

11.25-11.50

Cytotoxic and functional autoantibodies in sudden cardiac death
Varvara A. Ryabkova (St. Petersburg, Russian Federation)

11.50-12.15

Beta-1-adrenergic receptor antibodies in acute coronary syndrome
Gabriela Riemekasten (Lübeck, Germany)

12.15-12.30

Neutralization of anti-beta1-receptor autoantibodies in dilated
cardiomyopathy by the aptamer BC 007: latest news from animal
studies and human phase I and II trials
Niels-Peter Becker (Berlin, Germany)

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

12.30-14.00

Posters B1 – B27: Guided poster presentation of selected posters of the Candidates for the Dresden Prize chaired by Dirk Reinhold

EASI FORUM MEETING (EASI members only)
Meeting room “Palaiszimmer”

12.30-14.00

**PRECISION MEDICINE IN THE CARE OF
RHEUMATOID ARTHRITIS**

14.00-15.30

Co-Chairs: Martin Aringer (Dresden, Germany)
Günter Steiner (Vienna, Austria)

Prevention of Rheumatoid Arthritis by early identification enabled through autoantibodies
Kevin D. Deane (Aurora, USA)

14.00-14.25

Association of autoantibody profiles in Rheumatoid Arthritis with clinical phenotypes and outcome
René E.M. Toes (Leiden, The Netherlands)

14.25-14.50

Autoantibodies to stratify Rheumatoid Arthritis patients into more meaningful subsets: Value of anti-PAD antibodies
Erika Darrah (Baltimore, USA)

14.50-15.10

Porphyromonas Gingivalis Peptidylarginine Deiminase from RA patient citrullinates major RA-autoantigens biomarkers for Interstitial Lung Disease Arthritis
Madeleine Jennings, B. Marklein, A.J. Ytterberg, R.A. Zubarev, Karen Münzner, D.V. Schaardenburg, L.A. van de Stadt, Gerd-Rüdiger Burmester, Karl Skriner (Berlin, Germany)

15.10-15.20

Immunogenicity of TNF α inhibitors: a cross-sectional and a prospective real-life experience in rheumatoid arthritis patients
Pier Luigi Meroni, Caterina Bodio, Claudia Grossi, Andrea Becciolini, Antonio Marchesoni, Matteo Filippini, Paola Migliorini, Roberto Caporali, Raffaele Pellerito, Francesco Ciccia, Piercarlo Sarzi-Puttini, Federico Perosa, Giuseppe Paolazzi, Ivana Hollan, Francesca Pregnotato, Maria Orietta Borghi (Milan, Italy)

15.20-15.30

COFFEE BREAK

15.30-16.00

16.00-18.00

ADVANCES IN RHEUMATOID ARTHRITIS DIAGNOSTICS

(sponsored by Thermo Fisher Scientific, Phadia AB)

Co-Chairs: Christian Fischer (Freiburg, Germany)
Johan Rönnelid (Uppsala, Sweden)

16.00-16.20

Diagnosis of Rheumatoid Arthritis and the special role of antibodies. Relevance of specificity
Martin Aringer (Dresden, Germany)

16.20-16.40

The importance of isotypes of RF and anti-CCP antibodies for diagnosis and prognosis of rheumatoid arthritis
Günter Steiner (Vienna, Austria)

16.40-17.00

CCP antibodies in early RA
Daniela Sieghart (Vienna, Austria)

17.00-17.15

Meta-Analysis on anti-CCP test
Carmen Andalucia (Madrid, Spain)

17.15-17.30

CCP antibodies in the LifeLines cohort Study
Annechien Lambeck (Groningen, The Netherlands)

17.30-17.45

Possible role of RA33 antibodies in RA diagnostics
Maresa Grundhuber (Freiburg, Germany)

17.45-18.00

Will genetic testing play a role in diagnosis of RA in the future?
Maryam Poorafshar (Uppsala, Sweden)

18.00-18.15

Departure by shuttle bus from the congress venue to the Dresden shipping pier 4

19.00-22.00

Elbe river cruise and Social Dinner onboard the river cruise ship "Gräfin Cosel"

NOVEL AUTOANTIGENIC TARGETS AND EMERGING TECHNOLOGIES FOR AUTOANTIBODY DETECTION
(sponsored by MEDIPAN GmbH and Generic Assays GmbH)

Co-Chairs: Dirk Roggenbuck (Dahlewitz, Germany)
Dimitrios Bogdanos (Larissa, Greece)

08.30-10.30

Development and clinical use of a technique to quantify autoantibodies in immune complexes
Johan Rönnelid (Uppsala, Sweden)

08.30-08.50

Artificial intelligence for automated pattern recognition
Rico Hiemann (Senftenberg, Germany)

08.50-09.10

A novel immunofluorescence method for the detection of anti-DFS70 antibodies
Esvet Mutlu (Antalya, Turkey)

09.10-09.20

The frequency and occurrence of the most common patterns of ANA in patients with rheumatoid arthritis and ankylosing spondylitis during infliximab treatment
Marharyta Volkava (Minsk, Belarus)

09.20-09.30

Antiphospholipid antibodies in clinical practice
Franco Franceschini (Brescia, Italy)

09.30-09.45

Profiling of criteria and non-criteria antiphospholipid antibodies in Russian patients with SLE
Olga Tkachenko (St. Petersburg, Russian Federation)

09.45-10.00

The significance of antibodies against glycoprotein 2 in Chinese inflammatory bowel disease patients
Shulan Zhang (Beijing, China)

10.00-10.10

Anti-GP2 autoantibodies are biomarkers of disease severity and prognosis of patients with primary sclerosing cholangitis (PSC)
Ewa Wunsch (Szczecin, Poland)

10.10-10.20

A location based prediction model in Crohn's disease regarding Chitinase 3-like 1 autoantibodies
Nora Sipeki (Debrecen, Hungary)

10.20-10.30

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

10.30-11.00

11.00-12.30

AUTOANTIBODIES IN MYOSITIS AND SYSTEMIC SCLEROSIS

Co-Chairs: Ger J.M. Pruijn (Nijmegen, The Netherlands)
Michael Mahler (San Diego, USA)

11.00-11.25

Autoantibodies to stratify systemic sclerosis patients into more meaningful subsets
Michael Mahler (San Diego, USA)

11.25-11.50

Anti-cN-1A (NT5C1A) autoantibodies in autoimmune and infectious diseases
Ger Pruijn (Nijmegen, The Netherlands)

11.50-12.10

Subcutaneous calcinosis in autoimmune inflammatory myopathies: updating the biomarkers for prospective studies
Carlos von Mühlen (San Diego, USA)

12.10-12.20

Primary biliary cholangitis-related serology in systemic sclerosis patients: a three-years follow up study
Lisa Florin, Kaat Rubben, Amber Vanhaecke, Katrien Devreese, Filip De Keyser, Vanessa Smith, Carolien Bonroy (Ghent, Belgium)

12.20-12.30

Profiling autoantibodies in idiopathic inflammatory myopathies, systemic sclerosis and systemic Lupus erythematosus
Quan-Zhen Li, Mei Yan, Chengsong Zhu, Li Wang, Indu Raman, Edward Wakeland, Xiaoxia Zuo (Dallas, USA)

12.30-14-00

LUNCH BREAK – POSTER AND EXHIBITION VIEWING

Posters C1-C23 (AUTOANTIBODIES IN ORGAN SPECIFIC AUTO-IMMUNE DISEASES): Guided poster presentation of selected posters chaired by Ulrich Sack

14.00-15.30

**EASI SYMPOSIUM:
DIAGNOSTIC MARKERS IN SYSTEMIC SCLEROSIS**

Co-Chairs: Jan Damoiseaux (Maastricht, The Netherlands)
Manfred Herold (Innsbruck, Austria)

14.00-14.25

Clinical spectrum of systemic sclerosis
Carlo Chizzolini (Geneva, Switzerland)

14.25-14.50

Spectrum of autoantibodies in systemic sclerosis
Carolien Bonroy (Ghent, Belgium)

14.50-15.10

Systemic sclerosis-related autoantibodies: why total multi-profiling is superior to isolated antigen-specific testing
Dimitrios Bogdanos (Larissa, Greece)

15.10 -15.30

Evaluation and verification of autoantibody profiles in systemic sclerosis
Ruben Smeets (Nijmegen, The Netherlands)

COFFEE BREAK

15.30-16.00

**IMMUNE RESPONSE ADVERSE EFFECTS OF CHECKPOINT
INHIBITOR TREATMENT AND ASPECTS OF AUTOIMMUNE
ETIOPATHOGENESIS**

16.00-18.00

Co-Chairs: Pier Luigi Meroni (Milan, Italy)
Emma de Moel (Leiden, The Netherlands)

Autoantibodies and other biomarkers in immune response
adverse effects of check-point inhibitor treatment
Emma de Moel (Leiden, The Netherlands)

16.00-16.30

Autoimmune diseases developed in lung cancer patients
treated with immune checkpoint inhibitors
Minoru Satoh (Kitakyushu, Japan)

16.30-17.00

Classification of IgG4 autoimmune diseases
Inga Koneczny (Vienna, Austria)

17.00-17.30

GUT-joint axis: are rheumatologic processes initiated by
enteric events?
*Aaron Lerner, Patricia Wusterhausen, Sandra Neidhöfer,
Torsten Matthias (Wendelsheim, Germany)*

17.30-17.50

CHI3L1 in IBD – A potential association with ASCA
*Claudia Deutschmann, Dirk Roggenbuck,
Peter Schierack (Senftenberg, Germany)*

17.50-18.00

EASI Austria & Germany Meeting (for EASI members only)
Meeting room "Palaiszimmer"

18.15-19.15

08.30-10.30

UPDATE ON ANTINUCLEAR ANTIBODY DETECTION

Part 1

Co-Chairs: Martin Blüthner (Karlsruhe, Germany)
Carlos Alberto von Mühlen (San Diego, USA)

08.30-08.50

2019 – ANA detection: real life and EULAR recommendations
Pier Luigi Meroni (Milan, Italy)

08.50-09.05

ANA nomenclature and detection strategies (IIFT vs. collagenose screen): experiences from proficiency testing and questionnaires (EASI)
Martin Blüthner (Karlsruhe, Germany)

09.05-09.20

ANA: solid phase assays versus indirect immunofluorescence
Xavier Bossuyt (Leuven, Belgium)

09.20-09.35

The behavior of pattern and titer of HEp-2 IFA in lupus patients according to disease activity status
Luis E.C. Andrade (São Paulo, Brazil)

09.35-09.50

AC-XX: beyond ICAP's 29 pattern
Manfred Herold (Innsbruck, Austria)

09.50-10.00

A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: a pilot study
Maria Infantino, Teresa Carbone, Mariangela Manfredi, Valentina Grossi, Antonio Antico, Maria Piera Panozzo, Ignazio Brusca, Maria Grazia Alessio, Giulia Previtali, Stefan Platzgummer, Luigi Cinquanta, Giusy Paura, Gaia Deleonardi, Maria Teresa Trevisan, Antonella Radice, Caterina Castiglione, Tiziana Imbastaro, Martina Fabris, Giampaola Pesce, Brunetta Porcelli, Lucia Terzuoli, Maria Concetta Sorrentino, Marilina Tampoia, Danilo Villalta, Maria Elisabetta Conte, Giuseppina Barberio, Nicoletta Gallo, Maurizio Benucci, Nicola Bizzaro (Florence, Italy)

10.00-10.10

A survey on methodological aspects of anti-nuclear antibody testing
Martine Vercammen, Sylvia Broeders, Carolien Bonroy, Wim Coucke, Laurence Lutteri, Sofie Schouwers, Lieve Van Hoovels, Xavier Bossuyt (Brussels, Belgium)

10.10-10.20

Feasibility of ANA IFA harmonization: analytical evaluation of candidate standards on four commercially available automated ANA IFA analyzers
Lieve Van Hoovels, Edward Chan, Luis Andrade, Kai Fechner, Daria Franceschi, Kishore Malyavantham, Bernd Stoeckl, Xavier Bossuyt (Aalst, Belgium)

10.20-10.30

Evaluation of anti-nuclear antibody test utilization patterns in Alberta
Alex C. Chin, Jeannine Viczko, Jan Willem Cohen Tervaert, Anthony Russell, Robert Ferrari, Joshua E. Raizman, Barry Kyle, Ann E. Clarke, Marvin J. Fritzler, Connie Prosser (Calgary, AB, Canada)

COFFEE BREAK – POSTER AND EXHIBITION VIEWING 10.30-11.00

UPDATE ON ANTINUCLEAR ANTIBODY DETECTION **11.00-12.30**
Part 2

Co-Chairs: Carlos Casiano (Loma Linda, USA)
Edward K.L. Chan (Gainesville, USA)

The clinical relevance of immunofluorescence AC patterns:
The ICAP perspective 11.00-11.30
Jan Damoiseaux (Maastricht, The Netherlands)

Current challenges in understanding the significance of the
anti-DSF70 autoantibody-antigen system 11.30-11.45
Carlos Casiano (Loma Linda, USA)

Anti-Ro52 reactivity is an independent and additional
serum marker in connective tissue diseases 11.45-12.00
Edward K.L. Chan (Gainesville, USA)

Anti-DFS autoantibodies as probes to characterize the
DFS70/LEDGFp75 interactome 12.00-12.10
*Greisha L. Ortiz-Hernandez, Evelyn Sanchez-Hernandez,
Shannalee R. Martinez, Michael Mahler, Carlos A. Casiano
(Loma Linda, USA)*

Multi-center study for the association of anti-p80/coilin
with anti-DFS70 in ANA positive patients 12.10-12.20
*Michael Mahler, Chelsea Bentow, Mary Ann Aure,
Fabrice Roup, Amanda Jiao, Luis E.C. Andrade, Maria Infantino,
Vincent Ricchiuti, Joe Adams, May Y. Choi, Meifeng Zhang,
Marvin J. Fritzler (San Diego, USA)*

Establishment of international autoantibody reference standards
for the detection of anti-NuMA, anti-multiple nuclear dots,
and anti-GW body autoantibodies 12.20-12.30
*Bing Zheng, Rodrigo A. Mora, Marvin J. Fritzler, Minoru Satoh,
Ignacio Garcia-De La Torre, Katherine Boylan, Kathryn Kohl,
Luis E.C. Andrade, Edward K.L. Chan (Gainesville, USA)*

LUNCH BREAK – POSTER AND EXHIBITION VIEWING 12.30-13.30

NOVEL AUTOANTIBODIES AND TECHNOLOGIES **13.30-15.10**

Co-Chairs: Xavier Bossuyt (Leuven, Belgium)
Thorsten Krieger (Hamburg, Germany)

Identification of nine unknown nuclear antigens as autoantibody
targets in systemic autoimmune diseases 13.30-13.40
*Zitao Zeng, Ramona Miske, Madeleine Scharf,
Yvonne Denno, Christian Probst, Winfried Stöcker,
Lars Komorowski (Lübeck, Germany)*

- 13.40-13.50 Protein array screening identifies biomarkers for differential and predictive diagnostics
Karen Münzner, Franziska Werner (Hennigsdorf, Germany)
- 13.50-14.00 Immunoglobulin G autoantibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts
Dana Quaden, Patrick Vandormael, Pieter Ruytinx, Piet Geusens, Johan Vanhoof, Frank Vandenabeele, Kurt de Vlam, Veerle Somers (Diepenbeek, Belgium)
- 14.00-14.10 Autoantibodies associated with Bronchiolitis Obliterans of chronic allograft dysfunction in lung transplantation
Quan-Zhen Li, Chengsong Zhu, Mei Yan, Leying Feng, Lance Terada, Vaidehi Kaza (Dallas, USA)
- 14.10-14.20 Identification of novel maternal autoantibodies for autism spectrum disorder using cDNA phage display
Rut Mazón-Cabrera, Patrick Vandormael, Veerle Somers (Diepenbeek, Belgium)
- 14.20-14.30 Value of anti-HNK1 antibodies in anti-MAG neuropathies: an analyse of 144 sera
José Boucraut, Alexandre Brodovitch, Jean Claude Antoine, Stéphane Paul, Shahram Attarian, Emilien Delmont (Marseille, France)
- 14.30-14.40 The importance of second level confirmatory IHC assay to confirm autoantibody CSF expression in a case of Morvan syndrome
Martina Fabris, Greta Macorig, Romina Milanic, Laura Cecotti, Maria Rachele Bianchi, Piera De Gaspari, Francesco Curcio, Michele Rana (Udine, Italy)
- 14.40-14.50 Holistic characterization of the repertoire of targeted autoantigens of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Christian P. Moritz, Oda Stoevesandt, Yannick Tholance, Carole Rosier, Karine Ferraud, Jean-Philippe Camdessaniché, Jean-Christophe Antoine (Saint-Étienne, France)
- 14.50-15.00 Incidence of antibodies against the node of Ranvier in a prospective cohort of 1000 CIDP
José Boucraut, Emilien Delmont, Alexandre Brodovitch, Shahram Jose Attarian and the French CIDP group (Marseille, France)
- 15.00-15.10 Simultaneous detection and quantification of DNA- and protein biomarkers in a microfluidic microbead chip
Stefan Rödiger, Franziska Dinter, Michal Burdukiewicz, Peter Schierack, Werner Lehmann, Joerg Nestler, Gregory Dame (Senftenberg, Germany)

15.10-15.45 Dresden Prize Award Ceremony & Conclusion

15.45-16.45 FAREWELL COFFEE BREAK

POSTER EXHIBITION

A AUTOANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES

A1 Single testing vs. double testing strategy in the screening of connective tissue disease: A comparison of clinical performance and reimbursement in Germany. *Carmen Andalucia, Martin Brandenburg, Sigrid Sjölander (Uppsala, Sweden)*

A2 Clinical evaluation of a particle-based multi-analyte technology for the detection of anti-Th/To autoantibodies using Th/To subunits Rpp25 and Rpp38. *Michael Mahler, Karl Norvell, Andrea Seaman, Marychel Tiongson, Charles Warren, Chelsea Bentow, Lorenzo Beretta (San Diego, USA)*

A3 Evaluation of two distinct assays for detection of anti-Th/To antibodies in systemic sclerosis: a cross-sectional study. *Janire Perurena-Prieto, Andrea Seaman, Karl Norvell, Chelsea Bentow, Eduardo Luis Callejas-Moraga, Alfredo Guillén-Del-Castillo, Laura Viñas-Gimenez, Ana Marín-Sánchez, Eva Balada-Prades, Vicent Fonollosa-Plá, María Sanz-Martínez, Carmen Pilar Simeón-Aznar (San Diego, USA)*

A4 Verification of the new chemiluminescent immunoassay for DFS protein 70 antibodies (anti-DFS70). *Lovorka Đerek, Andrea Tešija Kuna, Milena Njegovan, Ines Vukasović (Zagreb, Croatia)*

A5 Autoantibody's profile and clinical correlations in a cohort of IIM from a single center. *Micaela Fredi, Ilaria Cavazzana, Micol Frassi, Paolo Airò, Angela Ceribelli, Nice Carabellese, Marco Taglietti, Minoru Satoh, Angela Tincani, Franco Franceschini (Brescia, Italy)*

A6 Autoantibody profile in a cohort of Systemic Sclerosis patients from a single centre: clinical and serological associations. *Micaela Fredi, Ilaria Cavazzana, Marzia Garofalo, Nice Carabellese, Fabio Ferrari, Paolo Airò, Angela Tincani, Franco Franceschini (Brescia, Italy)*

A7 Anti-NXP2 antibodies: clinical and serological associations in a multicentric Italian study. *Micaela Fredi, Ilaria Cavazzana, Angela Ceribelli, Simone Barsotti, Maurozio Benucci, Lorenzo Cavagna, Ludovico De Stefano, Andrea Doria, Marco Fornaro, Federica Furini, Roberto Gerli, Mariagrazia Giudizi, Marcello Govoni, Anna Ghirardello, Luca Iaccarino, Fiorenzo Iannone, Maria Infantino, Alessandro Mathieu, Emiliano Marasco, Paola Migliorini, Boaz Palterer, Matteo Piga, Federico Pratesi, Antonella Radice, Valeria Ricceri, Carlo Selmi, Marilina Tampoia, Alessandra Tripoli, Giovanni Zanframundo, Angela Tincani, Franco Franceschini, on behalf of Forum Italiano per la Ricerca Malattie Autoimmuni (FIRMA); (Brescia, Italy)*

TUESDAY,
SEPTEMBER 10
(12.30) until
FRIDAY,
SEPTEMBER 13
(13.30)

A8 Addressing the diagnostic gap in rheumatoid arthritis by complementing the serology with genetic information. *Isabel Gehring, Daniela Sieghart, Leonid Padyukov, Yutao Fu, Sascha Swiniarski, Josef Smolen, Maryam Poorafshar, Günter Steiner, Lars Klareskog (Freiburg, Germany)*

A9 A bioinformatic analysis supports a role of human cytomegalovirus as a trigger of Systemic Sclerosis-specific autoantibodies. *Athanasios Gkoutzourelas, M. Barmakoudi, Dimitrios P. Bogdanos (Larissa, Greece)*

A10 Prevalence of anti-C5'N1A autoantibodies in a French cohort of patients with Inclusion Body Myositis. *David Goncalves, Thierry Vincent, Laure Gallay, Nathalie Streichenberger, Raul Juntas-Morales, Sylvain Dubucquoi, Daniela Lakomy, Catherine Johanet, Françoise Fortenfant, René-Louis Humbel, Xavier Bossuyt, Pascale Chretien, Benoit Nespola, Sophie Hue, Frédéric Coutant, Nicole Fabien (Pierre-Bénite, France)*

A11 Anti-PL-7 is the most frequent t-RNA-synthetase antibody in routine laboratory testing. *Michael L. Grünwald, Kai Pitterle (Augsburg, Germany)*

A12 ANA (HEp2) cytoplasmic IF-patterns AC-19 and AC-20 and myositis specific antibodies results. *Michael L. Grünwald, Irene Kolbe, Christina Kamp, Wolfgang Meyer (Augsburg, Germany)*

A13 Comparison study of four different methods for proteinase 3 and myeloperoxidase antibody detection. *Katarina Gugo, Gordana Juricic, Vedrana Drvar (Split, Croatia)*

A14 ICAP's recommendations to describe patterns observed on HEp-2 cells are broadly accepted in Austria. *Manfred Herold, Werner Klotz (Innsbruck, Austria)*

A15 Addition of cN-1A as a target for detection of autoantibodies associated with Inclusion Body Myositis to a multiparameter lineblot immunoassay for autoimmune inflammatory myopathies. *Julia Janz, Anthonina Ott, Thomas Scheper, Wolfgang Schlumberger, Wolfgang Meyer (Lübeck, Germany)*

A16 EliA DFS70 and other routine methods for detection of anti-DFS70 antibodies. *Werner Klotz, Manfred Herold (Innsbruck, Austria)*

A17 Immunofluorescence patterns on HEp-2 cells not included in ICAP's classification tree. *Werner Klotz, Manfred Herold (Innsbruck, Austria)*

A18 Evaluation and comparison of the analytical performance of autoimmune antibodies on the HOB BioCLIA® 1200 Automated Immunoassay Analyzer to the Phadia 250® System. *Christine Knies, Michael Olivo, Ralf Tönnies, Philipp von Landenberg (Schüttorf, Germany)*

A19 Increased sensitivity for PR3-ANCA using a novel chemiluminescence immunoassay. *Elion Hoxha, Rolf A.K. Stahl, Silke R. Brix, Torsten Witte, Florian Seebeck, Wolfgang Schlumberger, Cornelia Daehnrich (Hamburg, Germany)*

A20 Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis. *Corrado Campochiaro, Simon D. Lytton, Svetlana Nihtyanova, Dietmar Fuchs, Voon H. Ong, Cristopher P. Denton (Munich, Germany)*

A21 Clinical associations of anti-U11/U12 (RNPC-3) autoantibodies in patients with systemic sclerosis. *Carmen Pilar Simeón, Mary Ann Aure, Fabreze Roup, Chelsea Bentow, Janire Perurena, Maite Sanz, Alfredo Guillen, Ana Marín, Vicent Fonollosa, Eduardo Callejas, Michael Mahler (San Diego, USA)*

A22 Comparison of immunodominant epitope recombinant RNPC-3 and RNPC-3 peptide as a target of autoantibodies in patients with systemic sclerosis. *Michael Mahler, Chelsea Bentow, Fabreze Roup, Haiyan Hou, May Y. Choi, Marvin J. Fritzler (San Diego, USA)*

A23 Polymorphisms in *ikzf1* gene predict the non response to tumor necrosis factor alpha-blocking agents in Rheumatoid Arthritis patients. *Pier Luigi Meroni, Caterina Bodio, Claudia Grossi, Daniela Privitera, Elena Raschi, Andrea Becciolini, Antonio Marchesoni, Matteo Filippini, Carlo Selmi, Roberto Caporali, Raffaele Pellerito, Francesco Ciccia, Piercarlo Sarzi-Puttini, Francesca Pregnotato, Maria Orietta Borghi (Milan, Italy)*

A24 Immunogenicity of TNFalpha inhibitors: a cross-sectional and a prospective real-life experience in rheumatoid arthritis patients. *Pier Luigi Meroni, Caterina Bodio, Claudia Grossi, Andrea Becciolini, Antonio Marchesoni, Matteo Filippini, Paola Migliorini, Roberto Caporali, Raffaele Pellerito, Francesco Ciccia, Piercarlo Sarzi-Puttini, Federico Perosa, Giuseppe Paolazzi, Ivana Hollan, Francesca Pregnotato, Maria Orietta Borghi (Milan, Italy)*

TUESDAY,
SEPTEMBER 10
(12.30) until
FRIDAY,
SEPTEMBER 13
(13.30)

A25 Testing of anti-phosphatidylserine/prothrombin antibodies – Added value for APS diagnostics? *Veronika Mikulová, Irena Francová, Helena Posová, Tomáš Zima (Prague, Czech Republic)*

A26 What's behind the pattern? A new method to detect anti-DFS70 autoantibodies. *Jean-Luc Charuel, Hanna Berkner, Pascale Ghillani-Dalbin, Makoto Miyara, Lucile Musset (Paris, France)*

A27 Simultaneous detection and quantification of DNA- and protein biomarkers in a microfluidic microbead chip. *Stefan Rödiger, Franziska Dinter, Michał Burdukiewicz, Peter Schierack, Werner Lehmann, Joerg Nestler, Gregory Dame (Senftenberg, Germany)*

A28 Clinical performance of a novel Multi-Analyte Assay for the diagnosis of APS in a Spanish cohort. *Estibaliz Ruiz-Ortiz, Natalia Egri, Laura Rubio, Albert Pérez-Isidro, Andrea Seaman, Carlos Ramírez, Douglas Mackey, Ricard Cervera, Gerard Espinosa, Odette Viñas, Michael Mahler (Barcelona, Spain)*

A29 Reactivity profile of novel human monoclonal antibodies to SAE, TIF1 γ , MDA5 and NXP2. *Michaelin Richards, Andrea Seaman, Charles Warren, Adrian Saclolo, Carolina Auza, Kishore Malyavantham, Michael Mahler (San Diego, USA)*

A30 Serum calprotectin in the diagnostic work-up of Rheumatoid Arthritis. *Lieve Van Hoovels, Bert Vander Cruyssen, Laura Bogaert, Stéfanie Van Den Breemt, Xavier Bossuyt (Aalst, Belgium)*

A31 Prospective validation of a novel DFS70 immunoassay in samples with suspected ANA-associated autoimmune rheumatic diseases. *Olaf Nickel, Stephan Borte, Andreas Pöge, Michael Borte, Martin Brandenburg, Raik Wolf, Johannes Wolf (Leipzig, Germany)*

A32 The clinical performance of HEp-2 IIFA on the fully automated IFx 360 System. *Shuxia Zhou, Jeri Seiki, John Breneman (Hercules, USA)*

A33 The role of RA33 sotypes in early rheumatoid arthritis diagnostics. *Maresa Grundhuber, Daniela Sieghart, Günter Steiner, Josef Smolen, Thomas Bergman, Johan Askling, Maryam Poorafshar, Sascha Swiniarski (Freiburg, Germany)*

A34 Profiling of criteria and non-criteria antiphospholipid antibodies in Russian patients with SLE. *Olga Tkachenko, Sergey Lapin, Elizaveta Belolipetskaia, Irina Beliaeva, Valentina Myachikova, Alexey Maslyansky, Dirk Roggenbuck (St. Petersburg, Russian Federation)*

A35 A novel indirect immunofluorescent method for anti-DFS70 antibodies. *Pelin Onarer, Esvet Mutlu, Gözde Öngüt, Meral Gültekin (Antalya, Turkey)*

A36 The importance of isotypes of RF and anti-CCP antibodies for rheumatoid arthritis diagnostics. *Daniela Sieghart, Alexander Platzner, Paul Studenic, Maresa Grundhuber, Helmuth Haslacher, Günter Steiner (Vienna, Austria)*

A37 A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: a pilot study. *Maria Infantino, Teresa Carbone, Mariangela Manfredi, Valen)na Grossi, Antonio Antico, Maria Piera Panozzo, Ignazio Brusca, Maria Grazia Alessio, Giulia Previtali, Stefan Platzgummer, Luigi Cinquanta, Giusy Paura, Gaia Deleonardi, Maria Teresa Trevisan, Antonella Radice, Caterina Castiglione, Tiziana Imbastaro, Martina Fabris, Giampaola Pesce, Brunetta Porcelli, Lucia Terzuoli, Maria Concetta Sorrentino, Marilina Tampoia, Danilo Villalta, Maria Elisabetta Conte, Giuseppina Barberio, NicoleGa Gallo, Maurizio Benucci, Nicola Bizzaro (Florence, Italy)*

A38 Evaluation of anti-nuclear antibody test utilization patterns in Alberta. *Alex C. Chin, Jeannine Viczko, Jan Willem Cohen Tervaert, Anthony Russell, Robert Ferrari, Joshua E. Raizman, Barry Kyle, Ann E. Clarke, Marvin J. Fritzler, Connie Prosser (Calgary, AB, Canada)*

A39 Urinary soluble CD163 predicts disease activity in patients with ANCA-associated crescentic glomerulonephritis. *Joop Aendeker (Maastricht, The Netherlands)*

TUESDAY,
SEPTEMBER 10
(12.30) until
FRIDAY,
SEPTEMBER 13
(13.30)

B CANDIDATES FOR THE DRESDEN PRIZE

- B1** BC 007 neutralizes functional autoantibodies against G protein-coupled receptors: Results of the Phase 1 clinical trial proof successful mode of action. *Niels-Peter Becker, Johannes Müller, Annekathrin Haberland, Gerd Wallukat, Katrin Wenzel, Peter Göttel, Sarah Schulze-Rothe, Ingolf Schimke, Tuba Yilmaz, Ayse Abay, Anne Wallukat, Anne-Sophie Hönicke, Susanne Becker (Berlin, Germany)*
- B2** Comparison of commonly used dsDNA assay types in order to better support an accurate clinical diagnosis. *Katalin Böröcz, Zsuzsanna Csizmadia, Vivien Varga, Tímea Berki (Pécs, Hungary)*
- B3** Evaluation of maternal infertility related autoantibody test results in a three-year period. *Zsuzsanna Csizmadia, Katalin Böröcz, Vivien Varga, Noémi Balázs, Tímea Berki (Pécs, Hungary)*
- B4** CHI3L1 in IBD – A potential association with ASCA. *Claudia Deutschmann, Dirk Roggenbuck, Peter Schierack (Senftenberg, Germany)*
- B5** Porphyromonas Gingivalis Peptidylarginine Deiminase from RA patient citrullinates major RA-autoantigens biomarkers for Interstitial Lung Disease Arthritis. *Madeleine Jennings, B. Marklein, A.J. Ytterberg, R.A. Zubarev, Karen Münzner, D.V. Schaardenburg, L.A. van de Stadt, Gerd-Rüdiger Burmester, Karl Skriner (Berlin, Germany)*
- B6** Lamin A and isoform 2 of desmoplakin as novel targets of antibodies against the UH-RA.21 peptide. *Silke Loyens, Pieter Ruytinx, Liesbeth De Winter, Piet Geusens, Jean-Paul Noben, Patrick Vandormael, Veerle Somers (Hasselt, Belgium)*
- B7** Anti-PAD4 antibodies can help close the seronegative gap in Rheumatoid Arthritis. *Laura Martinez-Prat, Barbara Tolusso, Chelsea Bentow, Anna Laura Fedele, Clara Di Mario, Elisa Gremese, Michael Mahler (San Diego, USA)*
- B8** Identification of novel maternal autoantibodies for autism spectrum disorder using cDNA phage display. *Rut Mazón-Cabrera, Patrick Vandormael, Veerle Somers (Diepenbeek, Belgium)*

B9 The impact of prophylactic treatment of recombinant banana lectin on the innate immune response in TNBS induced colitis in C57BL/6 mice. *Radmila Miljković, Emilija Marinković, Ana Filipović, Ivana Lukić, Mina Popović, Zorana Lopandić, Marija Gavrović-Jankulović, Marijana Stojanović (Belgrade, Serbia)*

B10 Holistic characterization of the repertoire of targeted autoantigens of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). *Christian P. Moritz, Oda Stoevesandt, Yannick Tholance, Carole Rosier, Karine Ferraud, Jean-Philippe Camdessanché, Jean-Christophe Antoine (Saint-Étienne, France)*

B11 Epitope mapping for anti-FGFR3 autoantibodies in Sensory Neuropathy. *Christian P. Moritz, Lauriane Mohr, Yannick Tholance, Martin Jung, Evelyne Reynaud-Federspiel, Karine Ferraud, Jean-Philippe Camdessanché, Jean-Christophe Antoine (Saint-Étienne, France)*

B12 Anti-DFS autoantibodies as probes to characterize the DFS70/LEDGFp75 interactome. *Greisha L. Ortiz-Hernandez, Evelyn Sanchez-Hernandez, Shannalee R. Martinez, Michael Mahler, Carlos A. Casiano (Loma Linda, USA)*

B13 Multi-center study for the association of anti-p80/coilin with anti-DFS70 in ANA positive patients. *Michael Mahler, Chelsea Bentow, Mary Ann Aure, Fabrece Roup, Amanda Jiao, Luis E.C. Andrade, Maria Infantino, Vincent Ricchiuti, Joe Adams, May Y. Choi, Meifeng Zhang, Marvin J. Fritzler (San Diego, USA)*

B14 Screening for immunoglobulin A antibody reactivity in early axial spondyloarthritis identifies novel antigenic targets. *Dana Quaden, Janriama Sirait, Patrick Vandormael, Pieter Ruytinx, Kristoff Corten, Johan Vanhoof, Piet Geusens, Veerle Somers (Diepenbeek, Belgium)*

B15 Immunoglobulin G autoantibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts. *Dana Quaden, Patrick Vandormael, Pieter Ruytinx, Piet Geusens, Johan Vanhoof, Frank Vandenabeele, Kurt de Vlam, Veerle Somers (Diepenbeek, Belgium)*

B16 Diagnostic performance of anti-cyclic citrullinated peptide (CCP) 2 and CCP.1 assays in early rheumatoid arthritis. *Daniela Sieghart, Christian Konrad, Sascha Swiniarski, Helmuth Haslacher, Daniel Aletaha, Günter Steiner (Vienna, Austria)*

TUESDAY,
SEPTEMBER 10
(12.30) until
FRIDAY,
SEPTEMBER 13
(13.30)

B17 Seroreversion of autoantibodies to UH-RA.21 peptide is associated with CDAl remission in rheumatoid arthritis patients of the CareRA cohort. *Patrick Vandormael, Silke Loyens, Pieter Ruytinx, Liesbeth De Winter, Veerle Stouten, Piet Geusens, Patrick Verschueren, Veerle Somers (Diepenbeek, Belgium)*

B18 Autoantibodies as predictors of response to therapy in rheumatoid arthritis patients. *Daniela Sieghart, Alexander Platzter, Farideh Alasti, Paul Studenic, Maresa Grundhuber, Sascha Swiniarski, Stephan Blüml, Helmuth Haslacher, Josef Smolen, Günter Steiner (Vienna, Austria)*

B19 A location based prediction model in Crohn's disease regarding a novel serological marker, Chitinase 3-like 1 autoantibodies. *Nora Sipeki, Patricia Kovats, Claudia Deutschmann, Peter Schierack, Dirk Roggenbuck, Maria Papp (Debrecen, Hungary)*

B20 Identification of tumor autoantibody biomarker candidates for colon cancer by using high density peptide microarrays. *Regina Soldo, Peter Hettegger, Andrea Stadler, Markus Degeorgi, Stefan Stiller, Walter Pulverer, Stefanie Brezina, Gernot Leeb, Andrea Gsur, Andreas Weinhäusel (Vienna, Austria)*

B21 The frequency of occurrence and the most common patterns of antinuclear antibodies in patients with rheumatoid arthritis and ankylosing spondylitis during Infliximab treatment. *Marharyta V. Volkava, Alena V. Kundzer, Dirk Roggenbuck, Mandy Sowa (Minsk, Belarus)*

B22 Prevalence of anti-Ku antibodies in various connective tissue diseases measured by a novel particle based multi-analyte technology. *Andrea Seaman, Marychel Tiongson, Charles Warren, Gabriella Morozzi, Maria Grazia Bacarelli, Danilo Villalta, Maria Orietta Borghi, Pier Luigi Meroni, Albert Selva O'Callaghan, Michael Mahler (San Diego, USA)*

B23 Clinical comparison of Aptiva with QUANTA Flash for the detection of anti-dsDNA autoantibodies. *Charles Warren, Andrea Seaman, Michelle Anne Amio, Chelsea Bentow, Gabriella Morozzi, Maria Grazia Bacarelli, Danilo Villalta, John Hanly, Michael Mahler (San Diego, USA)*

B24 Evaluation of a novel bead based assay for the detection of HMGCR autoantibodies in Idiopathic Inflammatory Myopathies. *Michaelin Richards, Charles Warren, Andrea Seaman, Anna Ghirardello, Andrea Doria, Albert Selva O'Callaghan, Franco Fanceschini, Sophie Hue, Marvin J. Fritzler, Michael Mahler (San Diego, USA)*

B25 Novel anti-Thomsen-Friedenreich antigen-based immunoassay adds value to diagnosis and prognosis of Prostate cancer. *Franziska Werner, Felix Hart, Jens Schmidt (Hennigsdorf, Germany)*

B26 Identification of nine unknown nuclear antigens as autoantibody targets in systemic autoimmune diseases. *Zitao Zeng, Ramona Miske, Madeleine Scharf, Yvonne Denno, Christian Probst, Winfried Stöcker, Lars Komorowski (Lübeck, Germany)*

B27 Establishment of international autoantibody reference standards for the detection of anti-NuMA, anti-multiple nuclear dots, and anti-GW body autoantibodies. *Bing Zheng, Rodrigo A. Mora, Marvin J. Fritzler, Minoru Satoh, Ignacio Garcia-De La Torre, Katherine Boylan, Kathryn Kohl, Luis E.C. Andrade, Edward K.L. Chan (Gainesville, USA)*

C AUTOANTIBODIES IN ORGAN SPECIFIC AUTOIMMUNE DISEASES

C1 Evaluation of a novel chemiluminescent immunoassay for the detection of anti-intrinsic factor autoantibodies. *A. Llanes, Roger Albesa, E. Fitzgerald, Michael Mahler (San Diego, USA)*

C2 Diagnostic performance of indirect immunofluorescence microscopy and enzyme-linked immunosorbent assays in bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus. *Pieter De Kesel, Sofie De Schepper, Carolien Bonroy (Ghent, Belgium)*

C3 The importance of second level confirmatory IHC assay to confirm autoantibody CSF expression in a case of Morvan syndrome. *Martina Fabris, Greta Macorig, Romina Milanic, Laura Cecotti, Maria Rachele Bianchi, Piera De Gaspari, Francesco Curcio, Michele Rana (Udine, Italy)*

C4 Multiparameter assay for the detection of IgA antibodies in autoimmune gastrointestinal diseases. *Julia Janz, Anthonina Ott, Thomas Scheper, Wolfgang Schlumberger, Wolfgang Meyer (Lübeck, Germany)*

TUESDAY,
SEPTEMBER 10
(12.30) until
FRIDAY,
SEPTEMBER 13
(13.30)

C5 Multiparameter assay for the detection of IgG antibodies in autoimmune gastrointestinal diseases. *Julia Janz, Anthonina Ott, Thomas Scheper, Wolfgang Schlumberger, Wolfgang Meyer (Lübeck, Germany)*

C6 Novel ELISA to aid the diagnosis of autoimmune gastritis. *Alexander Kühnl, Sandra Saschenbrecker, Lars Komorowski, Christian Probst, Giampaola Pesce, Wolfgang Schlumberger, Cornelia Dähnrich (Lübeck, Germany)*

C7 A newly developed chemiluminescence immunoassay improves the detection of anti-PLA2R autoantibodies in primary membranous nephropathy. *Alexander Kühnl, Cornelia Dähnrich, Sandra Saschenbrecker, Iva Gunnarsson, Pierre Ronco, Hanna Debiec, Wolfgang Schlumberger (Lübeck, Germany)*

C8 Probiotics: If it does not help it does not do any harm in celiac disease. Really? *Aaron Lerner, Yehuda Shoenfeld, Torsten Matthias (Wendelsheim, Germany)*

C9 Serum antibody profiling reveals a stratification of healthy toddlers into low, intermediate and high IgG responders towards autoantigens, infectious agents, and vaccine antigens. *Quan-Zhen Li, Mei Yan, Patricia Pichilingue-Reto, Prithvi Raj, Igor Dozmorov, Edward K. Wakeland, Nicolai S.C. van Oers (Dallas, USA)*

C10 Identification of DAGLA as an autoantibody target in cerebellar or hippocampal degeneration. *Ramona Miske, Madeleine Scharf, Stefanie Hahn, Yvonne Denno, Farid Benkhadra, Nadine Rochow, Christian Probst, Bianca Teegen, Winfried Stöcker, Lars Komorowski (Lübeck, Germany)*

C11 Monitoring of drug level and anti-drug antibody production during vedolizumab therapy in patients with inflammatory bowel disease. *Gábor Nagy, Éva Török, Károly Palatka, Zsófia. Kébel, Péter Antal-Szalmás (Debrecen, Hungary)*

C12 Microbial transglutaminase is a potential driver of autoimmunity. *Ajay Ramesh, Aaron Lerner, Sandra Neidhöfer, Patricia Wusterhausen, Torsten Matthias (Wendelsheim, Germany)*

C13 Gastric parietal cell and intrinsic factor autoantibodies in children and young adults with type 1 diabetes. *Raivo Uibo, Aleksandr Peet, Kaire Heilman, Kaja Metsküla (Tartu, Estonia)*

C14 Evaluation and comparison of the analytical performance of autoimmune antibodies on the HOB BioCLIA® 6500 automated immunoassay analyzer to the Phadia 250® system. *Christine Knies, Michael Olivo, Ralf Tönnies, Philipp von Landenberg (Schüttorf, Germany)*

C15 Immunomics profiling of patients with systemic autoinflammatory diseases using protein microarrays. *Julie Krainer, Sandra Siebenhandl, Silvia Schönthaler, Sandra Nagy, Stephan Pabinger, Seza Özen, Dirk Foell, Marco Gattorno, Andreas Weinhäusel (Vienna, Austria)*

C16 Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. *Joseph A. Honorat, A. Sebastian Lopez-Chiriboga, Thomas J. Kryzer, Vanda A. Lennon, Lars Komorowski, Madeleine Scharf, Winfried Stöcker, Shannon R. Hinson, Sean J. Pittock, Christopher J. Klein, Andrew McKeon (Rochester, USA)*

C17 Neurochondrin neurological autoimmunity. *Shahar Shelly, Thomas J. Kryzer, Vanda A. Lennon, Lars Komorowski, Ramona Miske, Winfried Stöcker, Mark D. Anderson, Shannon R. Hinson, Sean J. Pittock, Andrew McKeon (Rochester, USA)*

C18 The significance of antibodies against Glycoprotein 2 in Chinese inflammatory bowel disease patients. *Shulan Zhang (Beijing, China)*

C19 Anti-GP2 autoantibodies are biomarkers of disease severity and prognosis in patients with primary sclerosing cholangitis (PSC). *Ewa Wunsch, Malgorzata Milkiewicz, Marcin Krawczyk, Marta Slimak-Mastrobuoni, Zakera Shums, Mary Ann Aure, Chelsea Bentow, Gary L. Norman, Dirk Roggenbuck, Piotr Milkiewicz (Szczecin, Poland)*

C20 Development of the first 1-step radioactive immunoassay for the detection of TRAb. *Johannes Roggenbuck (Dahlewitz, Germany)*

C21 Splice site mutation of FOXP3 gene in IPEX syndrome. *Beáta Tóth (Debrecen, Hungary)*

C22 Identification of RGS8 as an autoantibody target in paraneoplastic cerebellar syndrome. *Ramona Miske, Madeleine Scharf, Christian Borchers, Yvonne Denno, Bianca Teegen, Nadine Rochow, Christian Probst, Winfried Stöcker, Pawel Kermer, Lars Komorowski (Lübeck, Germany)*

C23 Pre-analytic evaluation of circulating calprotectin in serum and citrate plasma from healthy donors. *Jenna Memmolo, Roger Albesa, Emily FitzGerald, Maria Infantino, Mariangela Manfredi, Valentina Grossi, Maurizio Benucci, Francesca Li Gobbi, Alessandra Matucci, Filippo Sarra, Michael Mahler (San Diego, USA)*

The following companies/societies participate in the industrial exhibition and/or have made a generous sponsorship (in alphabetical order):

- Booth 6** **AESKU Group GmbH & Co. KG** (Wendelsheim, Germany)
www.aesku.com
- Booth 15** **AIT Austrian Institute of Technology GmbH** (Vienna, Austria)
www.ait.ac.at
- Booth 11** **AROTEC Diagnostics Ltd.** (Wellington, New Zealand)
www.arodia.com
- Booth 14** **Bio-Rad Laboratories, Inc.** (Benicia USA)
www.bio-rad.com
- BioSystems S.A.** (Barcelona, Spain)
www.biosystems.com
- Booth 17** **BÜHLMANN Laboratories AG** (Schönenbuch, Switzerland)
www.buhlmannlabs.ch
- Cambridge Protein Arrays Ltd.** (Cambridge, UK)
www.cambridgeproteinarrays.com
- Booth 16** **CellTrend GmbH** (Luckenwalde, Germany)
www.celltrend.de
- Direct AG** (Freiburg, Germany)
www.direct.com
- DLD Diagnostika GmbH** (Hamburg, Germany)
www.dld-diagnostika.de
- Booth 9** **D-tek s.a.** (Mons, Belgium)
www.d-tek.be
- Booth 12** **EUROIMMUN AG** (Lübeck, Germany)
www.euroimmun.de

GA Generic Assays GmbH (Dahlewitz, Germany)
www.genericassays.com

**German United Society for Clinical Chemistry and
Laboratory Medicine** (Bonn, Germany)
www.dgkl.de

Human Gesellschaft für Biochemica und Diagnostik mbH
(Wiesbaden, Germany)
www.human.de

IDS Immunodiagnostic Systems Deutschland GmbH
(Frankfurt, Germany)
www.idsplc.com

Inova Diagnostics, Inc. (San Diego, USA)
www.inovadx.com

Limbach Gruppe SE (Heidelberg, Germany)
www.limbachgruppe.com

medac GmbH (Wedel, Germany)
www.medac.de

MEDIPAN GmbH (Dahlewitz, Germany)
www.medipan.de

PEPPERPRINT GmbH (Heidelberg, Germany)
www.pepperprint.com

Seramun Diagnostica GmbH (Heideseen, Germany)
www.seramun.com

TestLine Clinical Diagnostics Ltd. (Brno, Czech Republic)
www.testlinecd.com

Theradiag (Croissy Beaubourg, France)
www.theradiag.com

ThermoFisherScientific, Phadia AB (Uppsala, Sweden)
www.phadia.com

**We thank these companies for helping
to make this symposium successful.**

Booth 1

Booth 4

Booth 5

Booth 19

Booth 10

Booth 1

Booth 13


Booth 3

Booth 7

Booth 8

Booth 18





Social programme

Tuesday,
September 10, 2019
18.00-22.00

Wednesday
September 11, 2019

Get together in the Industrial Exhibition of Congress Venue
(Dresden Fair, Hall 3)

Social Dinner onboard the river cruise ship “Gräfin Cosel” (90 EUR)

After visiting all famous castles in and around Dresden during our past DSA social events, this year we have chosen a different type of highlight: The Dresden Symposium on Autoantibodies “goes aboard”: We invite you to join us on a wonderful, romantic evening onboard the river cruise ship “Gräfin Cosel”, cruising up the river Elbe to Pillnitz castle.

We will have dinner in elegantly furnished lounges that provide stunning panoramic views of the river scenery, the three Elbe castles, old vineyards and the famous bridge “Blue Wonder”. Enjoy it!

18.15 Departure by shuttle bus from the congress venue (Dresden Fair)

18.30 Champagne reception at shipping pier number 4.

19.00 Beginning of the cruise

19.15 Social Dinner (no formal dress code)

22.00 The ship arrives again at pier number 4. Return by bus to the Congress venue (Dresden Fair), via InterCity hotel, B&B hotel, and Maritim Hotel

GREEN CONGRESS

Environmental protection and sustainability are important to us. The Dresden Symposium on Autoantibodies is a **Green Congress**. For short transportation distances, we are **only** working with local partners: catering, event technology and event equipment, local printing house, local security and cleaning companies. We have also managed to establish a mostly paperless congress organization. Furthermore, during the congress we use small reusable badges without lanyards and reusable long-life conference (cotton) bags. Our caterer only utilizes reusable porcelain tableware, glasses and cutlery, reusable and returnable glass bottle as well as linen tablecloths. The symposium waste is separated.

You can help us protect the environment: Use public transport instead of a car! You will get **free tickets** for city transportation at the congress desk. Local transport information and timetables please find at <https://www.dvb.de/en-gb/>

Chairman

Honorary Chair

Co-Chairmen

**International
Advisory Board**

Industrial Board

**National
Organizing
Committee**

Karsten Conrad, Germany

Yehuda Shoenfeld, Israel

Luis E.C. Andrade, Brazil
Marvin Fritzler, Canada
Edward K.L. Chan, USA
Ger J.M. Pruijn, The Netherlands
Günter Steiner, Austria

Martin Blüthner, Germany
Dimitrios P. Bogdanos, Greece
Xavier Bossuyt, Belgium
Carlos A. Casiano, USA
Elena Csernok, Germany
Jan Damoiseaux, The Netherlands
Manfred Herold, Austria
Pier Luigi Meroni, Italy
Carlos Alberto von Mühlen, Brazil
Johan Rönnelid, Sweden
Minoru Satoh, Japan
Joanna Sheldon, UK

Michael Mahler, Inova Diagnostics, Inc.
Nina Olschowka, Phadia GmbH,
Dirk Roggenbuck, Medipan GmbH
Wolfgang Schlumberger, EUROIMMUN
Medizinische Labordiagnostika AG

Rico Hiemann
Thorsten Krieger
Ulrich Sack
Werner Schößler
Clemens August Schulze Lohoff
Andreas Schwab
(Members of the Advisory Committee of the GFID e.V.)

GENERAL INFORMATION

Symposium Venue/ Workshop Venue

Address of the symposium and workshop venue:
Messe Dresden (Dresden Fair)
Messering 6, Tor 1
01067 Dresden

Registration office

September 9: 07.00 – 18.00 (only for workshop participants!)
September 10: 08.00 – 22.00
September 11: 08.00 – 18.30
September 12: 08.00 – 19.30
September 13: 08.00 – 17.00

Phone on site

+49 160 98 35 87 47 and +49 351 44 58 222

Language

English, no simultaneous translation

Organization (Registration, Reservation, Exhibition)

Silke Zwjatkow
GFID e.V.
Wasastraße 14
01219 Dresden, Germany
Phone +49 351 26 32 279
Fax +49 351 26 32 280
e-mail: gfid.ev@me.com

Registration fee (on site)

Participants	EUR 570
GFID members	EUR 550
Students/Residents	EUR 320
ICAP/IAS Workshops	EUR 120
One day ticket	EUR 190

(includes unlimited access to all scientific sessions, welcome reception, industrial exhibition, one copy of the electronic edition of the conference book)

Members of the Dresden University are free of charge.

Credit Points

The Saxon State Medical Chamber rated the event with a total of **44 credit points**.

Save the date:

**Welcome to the 15th Dresden Symposium on Autoantibodies,
Dresden, September 7 to September 10, 2021**



Society for the Advancement of Immunodiagnostics

In September of 2002, Dr. Karsten Conrad and colleagues founded the “Society for the Advancement of Immunodiagnostics” (Gesellschaft zur Förderung der Immunodiagnostik – GFID e.V.). Through its work the society wants to contribute to help patients with immunologically caused diseases receive an early diagnosis and adequate treatment – especially through the publication of specialized literature and the organization of scientific meetings and workshops. Highlights are the biennial Dresden Symposia on Autoantibodies.

To be able to continue our non-profit work in the future, we would highly appreciate your support in searching funding and sponsoring opportunities.

www.gfid-ev.de

GFID E.V.
Ostsächsische Sparkasse Dresden
IBAN: DE63 8505 0300 3120 0593 57
BIC (SWIFT): OSDDDE81XXX

Together,
let's transform
autoimmune
diagnostics.



Lead your lab to the forefront

Learn how you can lead your lab and clinicians forward by closing the seronegative gap and increasing the efficiency and confidence of diagnosis. **Visit us at booth 19.**

Contact us or visit our website for more information
inovadx.com · info@inovadx.com · +1.858.586.9900

 **Inova
Diagnostics**
A Werfen Company